Compare SRCE & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRCE | IMCR |
|---|---|---|
| Founded | 1863 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1995 | 2016 |
| Metric | SRCE | IMCR |
|---|---|---|
| Price | $73.60 | $31.24 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $73.25 | $66.33 |
| AVG Volume (30 Days) | 134.5K | ★ 397.6K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | 19.59 | ★ 30.39 |
| EPS | ★ 6.41 | N/A |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | $10.29 | $14.57 |
| Revenue Next Year | $3.16 | $8.21 |
| P/E Ratio | $11.58 | ★ N/A |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $53.63 | $27.06 |
| 52 Week High | $75.16 | $40.71 |
| Indicator | SRCE | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 68.71 | 49.67 |
| Support Level | $65.26 | $31.08 |
| Resistance Level | N/A | $31.65 |
| Average True Range (ATR) | 1.42 | 1.15 |
| MACD | 0.44 | 0.18 |
| Stochastic Oscillator | 82.40 | 59.80 |
1st Source Corp provides specialized financing services for construction equipment, aircraft, and vehicle types through its Specialty Finance activities. The company offers commercial, small business, agricultural, and real estate loans, along with commercial leasing, treasury management, and payment services, including Fedwires, ACH, and merchant services. It also provides Renewable Energy Financing for commercial solar projects, a full range of consumer banking products, Trust and Wealth Advisory Services, and insurance products. The company operates in the commercial banking segment, which provides commercial and consumer banking services, trust and wealth advisory services, and insurance to individual and business clients across its markets.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.